Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 4/20 | 0.33 |
| ▸ | ACACA | Q13085 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655999 | 0.89 | PGR (0.38) | PGRKDM4EALDH1A1GAANOTUM | |
| SCHEMBL1550368 | 0.84 | PGR (0.42) | PGRACACBACACAMAPTALDH1A1 | |
| SCHEMBL5657600 | 0.78 | SLC9A1 (0.38) | MAPTKDM4EALDH1A1GAA | |
| SCHEMBL2362821 | 0.77 | KDM4E (0.36) | ACACBACACAKDM4EALDH1A1GAA | |
| SCHEMBL1550846 | 0.77 | PGR (0.38) | PGRACACBACACAMAPT | |
| SCHEMBL5657030 | 0.75 | CES1 (0.30) | — | |
| SCHEMBL27698252 | 0.72 | PGR (0.39) | PGRACACBACACANOTUM | |
| SCHEMBL3036687 | 0.72 | PGR (0.43) | PGRMAPTKDM4EALDH1A1GAA | |
| SCHEMBL11025445 | 0.72 | ACACB (0.38) | PGRACACBACACAMAPTKDM4E | |
| SCHEMBL2362432 | 0.72 | ACACB (0.34) | PGRACACBACACAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-7183238-B2 | [1,2]-oxazine-3,5-diones | BAYER CROPSCIENCE AG (DE) | 2007-02-27 | — | — | US | disclosed |
| US-20050070707-A1 | microbicides, pesticides and herbicides | BAYER CROPSCIENCE AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | PGR 305/4885ACACB 310/4885ACACA 541/4885 |
| US-20120129833-A1 | CYCLIC KETOENOLS FOR THERAPY | CYP46A1, LIPC, CYP27A1 | PGR 1372/4885ACACB 85/4885ACACA 90/4885 |
| US-20050070707-A1 | microbicides, pesticides and herbicides | DDT, CX3CR1, MSR1 | PGR 4047/4885ACACB 1887/4885ACACA 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.